Serina Therapeutics, Inc. SER
1.65 USD -0.04 (-2.37%)
At closeNov 5, 2026, 4:00 PM EST
1.72 +0.07 +4.24%
After hours · Nov 5, 4:00 PM ET
1.61 Day range 1.71
1.22 52-week range 4.45
- YTD
- -13.61%
- 1 year
- -61.89%
News
globenewswire.com Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC) Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for…
globenewswire.com Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo Translational data…
businesswire.com Custom Truck One Source, Inc. Reports Record Third Quarter 2026 Results and Increases Full Year 2026 Adjusted EBITDA and SER Revenue Guidance KANSAS CITY, Mo.--(BUSINESS WIRE)--Custom Truck One Source, Inc. (NYSE: CTOS), a leading provider of specialty equipment to the electric utility, telecom, rail, forestry, waste management and other…
globenewswire.com Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube
globenewswire.com Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress" Featuring Serina Therapeutics' CEO - Thursday, September 24, 2026 10M people in the world currently living with Parkinson's disease with no major clinical advances in 50+ years Meet with Serina's CEO…
defenseworld.net Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Sees Significant Decline in Short Interest Serina Therapeutics, Inc. (NYSEAMERICAN:SER - Get Free Report) was the recipient of a significant drop in short interest during the month of August. As of August 31st, there was short interest…
globenewswire.com Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference HUNTSVILLE, AL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ…
benzinga.com Serina Therapeutics Receives Recommendation From Independent Safety Monitoring Committee To Continue Its Phase 1b Registrational Trial Of SER-252 To Cohort 2 Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today…
globenewswire.com Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2 - Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose…
benzinga.com Serina Therapeutics Q2 EPS $(0.55) Misses $(0.47) Estimate, Sales $130.000K, Same YoY Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.47) by 19.57 percent. This is a 16.67 percent increase over losses of…
globenewswire.com Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ…
globenewswire.com Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ…
benzinga.com Serina Therapeutics Completes Enrollment And Dosing In Cohort 1 Of Ongoing Phase 1b Registrational Clinical Trial Evaluating SER-252 In Patients With Advanced Parkinson’s Disease - All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 -- Independent Safety Monitoring Committee to review Cohort 1 safety…
globenewswire.com Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease - All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1…
globenewswire.com Serina Therapeutics Appoints Farrell Simon to its Board of Directors HUNTSVILLE, Ala. , July 22, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its proprietary POZ…
marketbeat.com Seres Therapeutics' SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study Seres Therapeutics NASDAQ: MCRB reported results from an investigator-sponsored study of SER-155 in immune checkpoint inhibitor-related enterocolitis, or irEC, saying the data support further…
globenewswire.com Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease Data Safety Monitoring Committee completed initial review of sentinel dosing observations and recommended continued dosing in Cohort 1 - Dosing of additional patients in Cohort 1 is underway at sites…
globenewswire.com Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment 80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan…- benzinga.com BTIG Initiates Coverage On Serina Therapeutics with Buy Rating, Announces Price Target of $8 BTIG analyst Thomas Shrader initiates coverage on Serina Therapeutics (AMEX:SER) with a Buy rating and announces Price Target of $8.
benzinga.com Gannet BioChem To Support Development Activities For SER-252, Serina Therapeutics' Investigational Therapy For Advanced Parkinson's Disease Gannet BioChem, a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE:SER), a clinical-stage biotechnology company advancing…
globenewswire.com Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program HUNTSVILLE, Ala., June 30, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem , a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE…
globenewswire.com Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line…
benzinga.com Serina Therapeutics Files Prospectus For Offering 16.45M Common Shares On Behalf Of Selling Stockholders https://www.sec.gov/Archives/edgar/data/1708599/000149315226025007/forms-3.htm- benzinga.com Serina Therapeutics Says Phase 1b Registrational Clinical Study of SER-252 Underway In Advanced Parkinson's Disease; TFL Data From The SAD Study Arm Targeted For First Half of 2027 SER-252 Phase 1b Registrational Clinical Study: Following dosing of the first patient in February 2026, Serina continues to advance its Phase 1b registrational clinical study of SER-252 in advanced…
- benzinga.com Serina Therapeutics Q1 EPS $(0.58) Misses $(0.44) Estimate Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.44) by 31.82 percent. This is a 18.37 percent decrease over losses of…
globenewswire.com Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data from the SAD study arm targeted for first half of 2027 -
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Serina Therapeutics Q4 EPS $(0.31) Beats $(0.46) Estimate Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.46) by 32.61 percent. This is a 29.17 percent decrease over losses of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Stock Market Today: Futures Drop Ahead Of 'Triple Witching' Session As Iran Threatens 'Zero Restraint'— FedEx, Super Micro In Focus (UPDATED) (Editor’s note: The future prices of benchmark tracking ETFs, and the headline were updated in the story.) U.S. stock futures declined on Friday following Thursday’s declines. Futures of the major…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Gold Tumbles Over 6%; Accenture Earnings Top Views 
benzinga.com Dow Falls Over 300 Points; US Initial Jobless Claims Fall US stocks down, Dow falls 300+ points, S&P 500 drops 0.93%, Nasdaq falls 1.25%. Energy shares up, materials down. Initial jobless claims down 8,000.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why Five Below Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket Five Below Inc (FIVE) shares rose 7.2% in pre-market trading after reporting better-than-expected Q4 results and issuing strong FY26 EPS guidance. Other gainers include LBGJ, ASNS, SVRN, SUNE, MDAI,…
benzinga.com Serina Therapeutics (SER) Stock Surges Over 39% After Hours— Here's Why Serina Therapeutics Inc. surged 39.45% in after-hours trading Wednesday following a $15 million private placement announcement.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Serina Therapeutics Announces Up To $30M In Private Placement To Support Registrational Trial Of SER-252 Parkinson's Treatment - First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Serina Therapeutics Doses First Patient In Phase 1b Registrational Clinical Trial Evaluating SER-252 In Patients With Advanced Parkinson's Disease - Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 –- Advancement reflects continued execution of…
benzinga.com Xpeng, Serina Therapeutics, Dragonfly Energy Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why DarkIris Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why Meta Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session